AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02300064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise test with restricting/releasing blood flow
Description: 10 minute submaximal (20 Watts) single leg knee-extensor exercise with blood flow clamped 10-15% lower by arterial infustion of phenylephrine; 10 minute passive single leg knee-extensor exercise with blood flow matched to the 20 Watt work rate level by arterial adenosine infusion; 10 minute seated rest with blood flow matched to the 20 Watt work rate level by adenosine infusion. Each test separated by at least 30 minutes rest.
Study NCT02300064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise test with variable oxygen concentration and MRI
Description: Two bouts of single leg knee-extensor exercise to maximal effort breathing regular air (21% oxygen) or 100% oxygen through a mouthpiece, with a 90 minute rest period between each bout. The same experiment performed again on a separate day in an magnetic resonance imaging (MRI) machine
Study NCT01679119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4mg/m2(max 2mg)IV given day 1
Study NCT01679119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 100mg OD Oral given days 1-5
Study NCT01679119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 100mg OD Oral given days 1-5
Study NCT01679119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375mg/m2 IV given day 1
Study NCT01679119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m2 IV given day 1
Study NCT01679119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
Study NCT01679119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
Study NCT02300064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise test with oral antioxidant or placebo cocktail
Description: Antioxidants (Vitamin E - 400 international units, Vitamin C - 1000 milligrams and Alpha lipoic acid - 600 milligrams) or matching placebo capsules administered orally followed by femoral nerve stimulation and single leg knee-extensor exercise for 30 minutes at 50% maximum effort
Study NCT02430935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training
Description: Cognitive Adaptation Training (CAT) is a manual-driven standardized approach that uses environmental supports to improve multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia. Interventions for each functional deficit are based on two dimensions 1) level of impairment in executive functions (determined by neurocognitive tests) and 2) whether the overt behavior of the individual is characterized more by apathy (poverty of speech/movement/inability to initiate and follow through on behavioral sequences), disinhibition (distractibility/behavior which is highly cue-driven) or a combination of these styles (based on the Frontal Lobe Personality Scale (FLOPS).
Study NCT02430935 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action Based Cognitive Remediation
Description: ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
Study NCT01642888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-Tb
Description: The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
Study NCT01642888 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 T.U. Tuberculin PPD RT 23 SSI
Description: The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
Study NCT03852381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Paresthesia-based SCS(PB-SCS), with stimulating frequencies between 30 to 80 Hz that confer a tingling sensation. Three different paresthesia-free SCS (PF-SCS) modes that use frequencies in the range of 400-10,000 Hz include Burst, High Frequency stimulation at 1.2 kHz and High Density stimulation at 400 Hz.
Study NCT04382118 — intervention group
Intervention type: OTHER
Intervention: Data collection from routine medical records
Description: Data collection from routine medical records (clinical and radiological data)
Study NCT01886547 — intervention group
Intervention type: OTHER
Intervention: Prostate health screening
Study NCT04010617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pharyngeal Electrical Stimulation (PES)
Description: PES will be delivered by a commercial device (Phagenyx, Phagenesis Ltd, Manchester, UK), which comprises a nasogastric feeding catheter that houses stimulation ring-electrodes and a computerised base station that delivers stimulation in the range 1-50 mA at 5 Hz.
Study NCT01641887 — intervention group
Intervention type: OTHER
Intervention: Decision Aid
Description: Patients will use a decision aid administered on a computer.
Study NCT04624698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent Inject Implantation
Description: Subjects will be implanted with the iStent Injection Micro-Bypass device
Study NCT02310438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Instrumental Music Performance
Description: The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.
Study NCT02310438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Instrumental Music Performance
Description: The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.
Study NCT02277626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro Flo 5000
Description: Airway clearance device
Study NCT02277626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incourage Vest System
Description: Airway Clearance Device
Study NCT04877301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Description: Ultrasound guidance used to facilitate insertion of PIV catheter
Study NCT04877301 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-ultrasound guidance
Description: Ultrasound guidance will not be used for insertion of PIV catheter
Study NCT03440632 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FES
Description: Functional electrical stimulation of the ankle dorsiflexors during walking, using a (superficial) neurostimulator with tilt sensor.
Study NCT03888131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo
Description: Fixed combination of beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg (BDP/FF)
Study NCT03888131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo
Description: Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (BUD/FF)
Study NCT03949283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ChemoID Assay
Description: The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill bulk of tumor cells, and cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse.
Study NCT03949283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ChemoID Assay
Description: The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill bulk of tumor cells, and cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse.
Study NCT01027910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-24781
Description: Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle
Study NCT03949283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy
Description: Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin; Docetaxel; Paclitaxel; Carboplatin; Cisplatin; Gemcitabine; Topotecan; Carboplatin, Gemcitabine; Cisplatin, Gemcitabine; Carboplatin, Liposomal Doxorubicin; Carboplatin, Paclitaxel; Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab.
Study NCT03375996 — intervention group
Intervention type: DRUG
Intervention: cyclopentolate 0.5% eye drops
Description: cyclopentolate 0.5% eye drops and measurement of the pupillary mydriasis (dilatation)
Study NCT04372563 — intervention group
Intervention type: OTHER
Intervention: aortic prosthetics
Description: aortic prosthetics
Study NCT01027910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered intravenously on Day 4 of each 3 week cycle
Study NCT01027910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF
Description: Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2
Study NCT03096548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Safety Ink! Program
Description: The intervention will be comprised of an online skin cancer prevention training for all tattoo artists of participating studios. The training will include skin cancer rates and risk factors, tattoo rates, recommendations for sun protection practices, a rationale for the relationship of tattoo care and sun safety, and recommended communication strategies for artists to communicate skin cancer prevention to their clients. Additional printed materials (tip-card for clients, posters) to be displayed in tattoo studios, a Sun Safety Ink! website, and social media messages for tattoo studios' Facebook and Pinterest pages will be provided.
Study NCT03096548 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Studios and artists in this attention control group will not receive the Sun Safety Ink! program. They will continue to provide standard aftercare instructions to clients. The program will be provided to them at the end of the study.
Study NCT04297046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCA (patient controlled analgesia)
Description: Intravenous Patient-Controlled Analgesia was used for postoperative pain control with a bolus dose of 25 mg Tramadol and a lockout interval of 20 min. The pain was evaluated at different times after the operation, both at rest and movement (Dynamic VAS) at the 0., 2., 6., 12. hours and 24h later. All patients received 1 g iv paracetamol 8 hourly intervals regularly. 75 mg im diclofenac sodium was given as rescue analgesic.
Study NCT00352534 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Patients undergo radiotherapy
Study NCT01928264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Study NCT01235754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal testosterone gel 1%
Description: 300 mcg once daily transdermal testosterone gel 1%
Study NCT01235754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: once daily transdermal placebo gel
Study NCT00707239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline
Description: An initial intravenous (IV) loading dose of 150 mg of tigecycline, followed by 75 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
Study NCT00707239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigecycline
Description: An initial intravenous (IV) loading dose of 200 mg of tigecycline, followed by 100 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
Study NCT00707239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imipenem/cilastatin
Description: Imipenem/cilastatin 1g intravenous (IV) will be administered approximately every 8 hours, for up to 14 consecutive days. In addition vancomycin 15 mg/kg IV approximately every 12 hours (q12h), an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and ceftazidime placebo will be given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
Study NCT02877901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long acting tolterodine 4 mg
Description: receive one tablet at bed time for 4 weeks
Study NCT00352534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT00352534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest X-ray
Study NCT00352534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT00352534 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV
Study NCT00352534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00352534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT00352534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT00352534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT01256645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood transfusion
Description: application of single units of red blood cell transfusions
Study NCT04214808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-208
Description: Dutasteride 0.2mg
Study NCT04214808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avodart Soft Capsule 0.5mg
Description: Dutasteride 0.5mg
Study NCT02864953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB093
Description: Administered as specified in the treatment arm.
Study NCT02864953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT03356834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide(TAF)
Description: 25 mg tablet administered orally once daily
Study NCT03356834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate(TDF)
Description: 300 mg tablet administered orally once daily
Study NCT04024722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro Fertilization
Description: Patients suitable for research with poor ovarian response will receive treatment including laparoscopic surgery, resection, and transplantation of ovarian tissue in the same operation to improve the chances of success of in vitro fertilization and pregnancy. Participants will be assessed for surgical incisions and fertility assessment up to two weeks after treatment, including general physical examination, US pelvic examination, and blood tests for a hormonal profile to determine the initiation of ovarian stimulation and IVF. Patients will be monitored from 2 weeks to 1 year after treatment (once a week in the first two months and one month for one year after surgery), which will include a general physical examination, a US test, and blood tests for the hormonal profile at the IVF clinic.
Study NCT03944798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequency: Every 3 Months
Description: every 3 months
Study NCT03944798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frequency: Every 6 Months
Description: every 6 months
Study NCT03944798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequency: Every 6 Months
Description: every 6 months
Study NCT03944798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Imaging Modality: Chest Radiograph (CXR)
Description: Chest radiograph (CXR)
Study NCT03944798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Modality: Chest Radiograph (CXR)
Description: Chest radiograph (CXR)
Study NCT03944798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Modality: Chest CT
Description: Chest computed tomography (CT)
Study NCT02118818 — intervention group
Intervention type: GENETIC
Intervention: Next generation sequencing
Description: There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.
Study NCT01665014 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total marrow irradiation
Description: Mobilization of stem cells with the use of cytarabine 1.6 g/m2 followed by filgrastim 480 ug/d. Conditioning for the 1st autoHSCT: total marrow irradiation 4 Gy on days -3,-2,-1 (total 12 Gy). Conditioning for 2nd autoHSCT performed 3-4 months after the 1st one: melphalan 100 mg/m2 on days -2,-3 (total 200 mg/m2)
Study NCT03199495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: acupuncture needle with TENS device
Study NCT03199495 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: electroacupuncture
Description: acupuncture needle with TENS device
Study NCT02543229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPT-302
Description: OPT-302 will be administered by intravitreal injection once every month for 3 months
Study NCT02543229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis™
Description: Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months
Study NCT02877901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet at bed time
Study NCT03612713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Medication First
Description: Participants will be given 15mg oxycodone one hour before fMRI scan. After at least 1 week wash out participants will be given placebo one hour before fMRI scan.
Study NCT03612713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo First
Description: Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
Study NCT04654286 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve transfer procedure
Description: 1. Identification of potential donor nerves: phrenic nerve, accessory nerve, intercostal nerve, motor branch nerve innervating long head of triceps muscle, motor branch of ulnar nerve innervating flexor carpi ulnaris (FCU) muscle, and motor branch of median nerve innervating flexor carpi radialis (FCR) muscle.~2. Donor nerve is checked for its viability with an electric stimulator during surgery~3. Viable donor nerve is dissected, transferred to the recipient area, and sutured with end-to-end anastomosis.